Blocking the Entrance

Entry inhibitors usher in a new phase of hep C research by Larry Buhl Future therapy for hepatitis C infection may include a variety of drugs...

Care Crusade

HIVHealthReform.org offers chances to learn about & advocate for new policies by Chael Needle The Patient Protection and Affordable Care Act, created by the Obama administration,...

Building Success

When it comes to Effective HIV reform, don’t throw the baby out with the bathwater by Mariel Selbovitz, MPH, and Leslie G Selbovitz, MD LifeGuide Extensive progress in...

Taking a Toll

LifeGuide Hep C is surpassing HIV as a deadlier disease by Larry Buhl There was a new milestone reached last month when a new study suggested...

Protecting the Pipeline

LifeGuide HIV drug development faces challenges by Jeannie Wraight and Mariel Selbovitz, MPH Triple and now quad drugs like Gilead’s Atripla and their new compound known...

Right Around the Corner

New meds offer hope for interferon-free regimen by Larry Buhl LifeGuide In the past year several protease inhibitors were introduced for chronic hepatitis C, marking a...

Red Flags

LifeGuide African Americans face medical barriers to HCV treatment by Larry Buhl In the U.S. blacks are disproportionately infected with the hepatitis C virus (HCV), and...

Step Up

LifeGuide HCV testing targets baseball lovers by Larry Buhl This summer a pilot program was launched to raise awareness of the importance of testing for the hepatitis...

Treatment as Prevention

LifeGuide A community perspective on PrEP delves into its pros & cons by Jeannie Gibbs Post-exposure prophylaxis (PrEP) is the provision of antiretrovirals (ARVs) to HIV-negative...

Status Update

LifeGuide Based in San Diego, a prevention model aims to reach everyone Everybody should be tested for HIV. That message is the basis for Lead...

LATEST POSTS

FDA Approves Truvada as PrEP for Adolescents

On May 18, 2018, Gilead Sciences, Inc., announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral Truvada for use as...